Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 657-667

  Boonstra, Andre ^a   Liu, Bi Sheng ^a   Groothuismink, Zwier M A ^a   Bergmann, Jilling F ^a   De Bruijne, Joep ^b   Hotho, Daphne M ^a   Hansen, Bettina E ^a   Van Vliet, Andre A ^c   Van De Wetering De Rooij, Jeroen ^c   Fletcher, Simon P ^d   Bauman, Lisa A ^d   Rahimy, Mohamad ^d   Appleman, James R ^d   Freddo, James L ^d   Reesink, Hendrik W ^b   De Knegt, Robert J ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c PRA Health Sciences   (Netherlands)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANA 773; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PLACEBO; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE COUNT; MALE; MYELOID DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON INDUCERS; LYMPHOCYTES; MALE; MIDDLE AGED; PRODRUGS; RNA, VIRAL; TOLL-LIKE RECEPTOR 7; YOUNG ADULT;

EID: 84861658289     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2023     Document Type: Article

References (26)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. (Pubitemid 41196755)
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 Suppl 1:S35-S46. (Pubitemid 35253462)
3. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58:391-424. (Pubitemid 39551992)
4. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-229. (Pubitemid 40364823)
5. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25:71-99. (Pubitemid 46697903)
6. Boonstra A, Woltman AM, Janssen HL. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol 2008; 22:1049-1061.
7. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961-966. (Pubitemid 41191672)
8. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511. (Pubitemid 38931765)
9. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995. (Pubitemid 41057715)
10. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194:863-870.
11. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151-161. (Pubitemid 37336516)
12. Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195:1507-1512. (Pubitemid 34602828)
13. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42:724-731. (Pubitemid 41233667)
14. Pockros PJ, Guyader D, Patton H, et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind Phase IIa studies. J Hepatol 2007; 47:174-182. (Pubitemid 47021257)
15. Liu B-S, Groothuismink ZMA, Janssen HLA, Boonstra A. Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections. J Leukoc Biol 2011; 89:981-988.
16. Bergmann JF, de Bruijne J, Hotho D, et al. Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011; 34:443-453.
17. Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, Parkinson T. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 2007; 51:2969-2978. (Pubitemid 47206238)
18. Yonkers NL, Rodriguez B, Milkovich KA, et al. TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol 2007; 178:4436-4444. (Pubitemid 46492395)
19. Simone O, Tortorella C, Zaccaro B, Napoli N, Antonaci S. Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. J Clin Immunol 2010; 30:556-565.
20. Chang S, Kodys K, Szabo G. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology 2010; 51:35-42.
21. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006; 108:3253-3261.
22. Schott E, Witt H, Neumann K, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCVinfection and response to interferon-a-based therapy. J Viral Hepat 2008; 15:71-78. (Pubitemid 350243584)
23. Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177:2088-2096. (Pubitemid 44200966)
24. Castro AG, Neighbors M, Hurst SD, et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med 2000; 192:1529-1534.
25. Boonstra A, Rajsbaum R, Holman M, et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol 2006; 177:7551-7558. (Pubitemid 44846270)
26. Lu H, Wagner WM, Gad E, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010; 184:5360-5367.